Protection against multiple influenza a virus strains induced by candidate recombinant vaccine based on heterologous m2e peptides linked to flagellin

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Stepanova, Liudmila A ^a   Kotlyarov, Roman Y ^b   Kovaleva, Anna A ^a   Potapchuk, Marina V ^a   Korotkov, Alexandr V ^a   Sergeeva, Mariia V ^a   Kasianenko, Marina A ^a   Kuprianov, Victor V ^b   Ravin, Nikolai V ^b,c   Tsybalova, Liudmila M ^a   Skryabin, Konstantin G ^b   Kiselev, Oleg I ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b INSTITUTE OF BIOENGINEERING   (Russian Federation)

^c GenNanotech Ltd   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 4; MATRIX 2 PROTEIN ECTODOMAIN RECOMBINANT VACCINE; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; PEPTIDE FRAGMENT; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; FEMALE; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; LUNG; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN; VIRUS TITRATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY; VIRUS LOAD; WESTERN BLOTTING;

AVES; AVIAN INFLUENZA VIRUS; INFLUENZA A VIRUS; MUS;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLAGELLIN; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84925799197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119520     Document Type: Article

References (78)

1. Zebedee SL, Lamb RA. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988; 62: 2762-2772. PMID: 2455818
2. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, et al. (2009) M2e-based universal influenza A vaccine. Vaccine. 2009; 27: 6280-6283. doi: 10.1016/j.vaccine.2009.07.007 PMID: 19840661
3. Liu W, Zou P, Chen Y-H. Monoclonal antibodies recognising EVETPRN epitope of influenza M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett. 2004; 93: 131-136. PMID: 15158608
4. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5: 1157-1163. PMID: 10502819
5. Mozdzanowska K, Feng JQ, Eid M, Kragol G, Cudic M, Otvos L, et al. Induction of influenza type A virus specific resistance by immunisation of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine. 2003; 21: 2616-2626. PMID: 12744898
6. De Filette M, Min JW, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimisation of M2-based constructs. Virology. 2005; 337: 149-161. PMID: 15914228
7. De Filette M, Fiers W, Martens W, Birkett A, Ramme A, Lowenadler B, et al. Improved design and intranasal delivery of an M2e-based human influenza A Vaccine. Vaccine. 2006; 24: 6597-6601. PMID: 16814430
8. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jecobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008; 26: 201-214. PMID: 18063235
9. Ameiss K, Ashraf S, Kong W, Pekosz A, Wu W-H, Milich D, et al. Delivery of woodchuck hepatitis viruslike particles presented influenza M2e by recombinant attenuated salmonella displaying a delayed lysis phenotype. Vaccine. 2010; 28: 6704-6713. doi: 10.1016/j.vaccine.2010.07.083 PMID: 20691653
10. Ravin NV, Kotlyarov RY, Mardanova ES, Kuprianov VV, Migunov AI, Stepanova LA, et al. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc). 2012; 77: 33-40. doi: 10.1134/S000629791201004X PMID: 22339631
11. Blokhina EA, Kuprianov VV, Tsybalova LM, Kiselev OI, Ravin NV, Skryabin KG. (2013) A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology. 2013; 435: 293-300. doi: 10.1016/j.virol.2012.09.014 PMID: 23062739
12. Kim M-C, Song J-M, O E, Kwon Y-M, Lee Y-J. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther. 2013; 21: 485-492. doi: 10.1038/mt.2012.246 PMID: 23247101
13. Ma J-H, Yang F-R, Yu H, Zhou Y-J, Li G-X, Huang M, et al. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Virol J. 2013; 10:227-232. doi: 10.1186/1743-422X-10-227 PMID: 23834899
14. Ben-Yedidia T, Tarrab-Hazdai R, Schechtman D, Arnon R. Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect Immun. 1999; 67: 4360-4366. PMID: 10456875
15. Lee LH, Burg E, Baqar S, Bourgeois AL, Burr DH, Ewing CP, et al. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immun. 1999; 67: 5799-5805. PMID: 10531231
16. Honko AN, Sriranganathan N, Lees CJ, Mizel SB. Flagellin is an effective adjuvant for immunisation against lethal respiratory challenge with Yersinia pestis. Infect Immun. 2006; 74: 1113-1120. PMID: 16428759
17. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, et al. A West Nile virus recombinant protein vaccine that co-activates innate and adaptive immunity. J Infect Dis. 2007; 195: 1607-1617. PMID: 17471430
18. Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol. 2008; 82: 3517-3529. doi: 10.1128/JVI.01854-07 PMID: 18199639
19. Bates JT, Honko AN, Graff AH, Kock N, Mizel SB. Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev. 2008; 129: 271-281. doi: 10.1016/j.mad.2008.01.009 PMID: 18367233
20. Bates JT, Uematsu S, Akira S, Mizel SB. Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol. 2009; 182: 7539-7547. doi: 10.4049/jimmunol.0804225 PMID: 19494277
21. Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of non-mucoid Pseudomonas aeruginosa. Infect Immun. 2009; 77: 2356-2366. doi: 10.1128/IAI.00054-09 PMID: 19349426
22. Eaves-Pyles TD, Wong HR, Odoms K, Pyles RB. Salmonella flagellin-dependent proinflammatory responses are localised to the conserved amino and carboxyl regions of the protein. J Immunol. 2001; 167: 7009-7016. PMID: 11739521
23. Donnelly MA, Steiner TS. Two non-adjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol Chem. 2002; 277: 40456-40461. PMID: 12185085
24. Mizel SB, West AP, Hantgan RR. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem. 2003; 278: 23624-23629. PMID: 12711596
25. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001; 410: 1099-1103. PMID: 11323673
26. Mizel SB, Snipes JA. Gram-negative flagellin-induced self-tolerance is associated with a block in inter-leukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem. 2002; 277: 22414-22420. PMID: 11953430
27. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunisation with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine. 2002; 20: 2772-2780. PMID: 12034104
28. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine. 2009; 27: 2099-2107. doi: 10.1016/j.vaccine.2009. 02.011 PMID: 19356612
29. Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine. 2009; 27: 5875-5884. doi: 10.1016/j.vaccine.2009.07.060 PMID: 19654064
30. Wang B-Z, Xu R, Quan F-S, Kang SM, Wang L, Compans RW. Intranasal immunisation with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE. 2010; 5: e13972. doi: 10.1371/journal.pone.0013972 PMID: 21124769
31. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, et al. Immunogenicity and efficacy of flagel-lin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLos ONE. 2011; 6(6): e20928. doi: 10.1371/journal.pone.0020928 PMID: 21687743
32. Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu H, et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine. 2012; 30: 6833-6838. doi: 10.1016/j.vaccine.2012.09.013 PMID: 23000130
33. Lin S-C, Lin Y-F, Chong P, Wu S-C. Broader neutralising antibodies against H5N1 viruses using primeboost immunisation of hyperglycosylated haemagglutinin DNA and virus-like particles. PLoS ONE. 2012; 7: e39075. doi: 10.1371/journal.pone.0039075 PMID: 22720032
34. Hong SH, Byun Y-H, Nguyen CT, Kim SY, Seong BL, Park S, et al. Intranasal administration of flagel-lin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine. 2012; 30: 466-474. doi: 10.1016/j.vaccine.2011.10.058 PMID: 22051136
35. Delaney KN, Phipps JP, Johnson JB, Mizel SB. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol. 2010; 23: 201-210. doi: 10.1089/vim.2009.0107 PMID: 20374000
36. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJM, Ferreira LC, et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine. 2010; 28: 2818-2826. doi: 10.1016/j.vaccine.2010.02.004 PMID: 20170765
37. Bobat S, Flores-Langarica A, Hitchock J, Marshall JL, Kingsley RA, Goodall M, et al. Soluble flagellin, FLiC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. Eur J Immunol. 2011; 41: 1606-1618. doi: 10.1002/eji.201041089 PMID: 21469112
38. Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares IS, Nussenzweig RS, et al. TLR5-depended immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella typhimurium. Mem Inst Oswaldo Cruz. 2011; 106 (suppl1): 167-171.
39. Gat O, Galen JE, Tennant S, Simon R, Blackwelder WC, Silverman DJ, et al. Cell-associated flagella enhance the protection conferred by mucosally-administrated attenuated Salmonella paratyphi A vaccines. PLOS ONE. 2011; 5: e1373.
40. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunisation with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine. 2011; 29: 5731-5739. doi: 10.1016/j.vaccine.2011.05.095 PMID: 21696869
41. Cuadros C, Lopez-Hernandez FG, Dominguez AL, McClelland M, Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun. 2004; 72: 2810-2816. PMID: 15102791
42. Munoz N, Van Maele L, Marques J.M, Rial A, Sirard JC, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumonia lung infection. Infect Immun. 2010; 78: 4226-4233. doi: 10.1128/IAI.00224-10 PMID: 20643849
43. Feng T, Cong Y, Alexander K, Elson CO. Regulation of toll-like receptor 5 gene expression and function on mucosal dendritic cells. PLOS ONE. 2012; 7: e35918. doi: 10.1371/journal.pone.0035918 PMID: 22545147
44. Arulanandam BP, Raeder RH, Nedrud JG, Bucher DG, Le J, Metzger DW. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol. 2001; 166: 226-231. PMID: 11123296
45. Bizanov G, Janakova L, Knapstad SE, Karstad T, Bakke H, Haugen IL, et al. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol. 2005; 61: 503-510. PMID: 15963044
46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63. PMID: 6606682
47. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 1990; 64: 1375-1377. PMID: 2304147
48. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol. 2005; 79: 6644-6654. PMID: 15890902
49. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol. 1991; 65: 5491-5498. PMID: 1895397
50. Liu W, Zou P, Ding J, Lu Y, Chen JH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza design. Microbes Infect. 2005; 7: 171-177. PMID: 15777646
51. Kotlyarov RY, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, et al. Development of recombinant vaccine against A(H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein. Acta Naturae. 2010; 2: 71-77. PMID: 22649643
52. Shim B-S, Choi YK, Yun C-H, Lee E-G, Jeon YS, Park SM, et al. Sublingual immunisation with M2-based vaccine induces broad protective immunity against influenza. PLOS ONE. 2011; 6(11): e27953. doi: 10.1371/journal.pone.0027953 PMID: 22140491
53. Petukhova NV, Gasanova TV, Stepanova LA, Rusova OA, Potapchuk MV, Korotkov AV, et al. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by tobacco mosaic virus-based vectors. Curr Pharm Des. 2013; 19: 5587-5600. PMID: 23394564
54. Andersson AM, Hakansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerising protein. PLOS One. 2012; 7(10): e46395. doi: 10.1371/journal.pone.0046395 PMID: 23049700
55. Chen LM, Blixt O, Stevens J, Lipatov AS, Davis ST, Collins BE, et al. In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology. 2012; 422: 105-113. doi: 10.1016/j. virol.2011.10.006 PMID: 22056389
56. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012; 486: 420-428. doi: 10.1038/nature10831 PMID: 22722205
57. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21: 335-376. PMID: 12524386
58. Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines. 2007; 6: 401-418. PMID: 17542755
59. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999; 17: 1075-1081. PMID: 10545912
60. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol. 2002; 169: 3914-3919. PMID: 12244190
61. Wang L, Wang Y-C, Feng H, Ahmed T, Compans RW, Wang B-Z. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin indice heterosubtypic protection in mice. BioMed Res Int. 2013; 686549. doi: 10.1155/2013/686549 Epub 2013 Jul 30.
62. Mozdzanovska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virology J. 2007; 4: 118 doi: 10.1186/1743-422X-4-118 PMID: 17974006
63. Mazanec MB, Coudred CL, Fletcher DR. Intracellular neutralisation of influenza virus by immunoglobulin A anti-haemagglutinin monoclonal antibodies J Virol. 1995; 69: 1339-13434. PMID: 7815518
64. Shibuya A, Honda S. Molecular and functional characteristics of the Fcalpha/muR, a novel Fc receptors for IgM and IgA. Springer Semin Immunopathol. 2006; 28: 377-382. PMID: 17061088
65. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172: 5598-5605. PMID: 15100303
66. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011; 186: 1022-1031. doi: 10.4049/jimmunol.0902147 PMID: 21169548
67. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclasses activity through selective Fc receptor binding. Science. 2005; 310: 1510-1512. PMID: 16322460
68. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with non-neutralising antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titre but fails to clear the infection. Virology. 1999; 254: 138-146. PMID: 9927581
69. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, Mohr E, et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol. 2004; 34: 2986-2995. PMID: 15384042
70. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, Carlsen H, et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol. 2004; 172: 6922-6930. PMID: 15153511
71. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine. 2007; 25: 763-775. PMID: 16968658
72. Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, Núñez G, et al. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur J Immunol. 2009; 39: 359-371. doi: 10.1002/eji.200838804 PMID: 19152336
73. Nimmerjahn F, Ravetch JV. Fc-gamma receptors: old friends and new family members. Immunity. 2006; 24: 19-28. PMID: 16413920
74. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol. 2007; 178: 2448-2457. PMID: 17277152
75. HazenbosWL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity. 1996; 5: 181-188. PMID: 8769481
76. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, et al. Universal vaccine against influenza virus: linking TLR signalling to anti-viral protection. Eur J Immunol. 2012; 42: 863-869. doi: 10.1002/eji.201041225 PMID: 22531913
77. Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MHZ. In contrast to conventional inactivated influenza vaccine, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology. 2012; 430: 63-72. doi: 10.1016/j.virol.2012.04.015 PMID: 22595444
78. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem. 2008; 283: 11382-11387. doi: 10.1074/jbc. M800650200 PMID: 18252707